- Home
- IMCR vs STR Comparison
IMCR vs STR Comparison
Compare IMCR & STR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- STR
- Stock Information
- Founded
- IMCR 2008
- STR 2016
- Country
- IMCR United Kingdom
- STR United States
- Employees
- IMCR N/A
- STR N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- STR Oil & Gas Production
- Sector
- IMCR Health Care
- STR Energy
- Exchange
- IMCR Nasdaq
- STR Nasdaq
- Market Cap
- IMCR 1.5B
- STR 1.4B
- IPO Year
- IMCR 2021
- STR N/A
- Fundamental
- Price
- IMCR $32.80
- STR $18.40
- Analyst Decision
- IMCR Buy
- STR Buy
- Analyst Count
- IMCR 10
- STR 6
- Target Price
- IMCR $58.13
- STR $25.40
- AVG Volume (30 Days)
- IMCR 444.9K
- STR 1.5M
- Earning Date
- IMCR 08-07-2025
- STR 08-06-2025
- Dividend Yield
- IMCR N/A
- STR 7.60%
- EPS Growth
- IMCR N/A
- STR N/A
- EPS
- IMCR N/A
- STR 0.52
- Revenue
- IMCR $333,581,000.00
- STR $636,538,000.00
- Revenue This Year
- IMCR $26.82
- STR N/A
- Revenue Next Year
- IMCR $8.15
- STR N/A
- P/E Ratio
- IMCR N/A
- STR $35.36
- Revenue Growth
- IMCR 25.75
- STR 7.18
- 52 Week Low
- IMCR $23.15
- STR $14.58
- 52 Week High
- IMCR $41.54
- STR $25.64
- Technical
- Relative Strength Index (RSI)
- IMCR 51.47
- STR 47.03
- Support Level
- IMCR $30.76
- STR $18.12
- Resistance Level
- IMCR $33.95
- STR $18.75
- Average True Range (ATR)
- IMCR 1.39
- STR 0.50
- MACD
- IMCR -0.15
- STR -0.17
- Stochastic Oscillator
- IMCR 43.05
- STR 16.73
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.